When starting bisphosphonate therapy for osteoporosis, what patient history, counseling points, and laboratory evaluations should be addressed during the clinic visit?

Starting Bisphosphonate Therapy for Osteoporosis: Essential Clinical Checklist

Before initiating bisphosphonate therapy, you must assess renal function, measure serum calcium and vitamin D levels, evaluate dental health, screen for contraindications to oral bisphosphonates (esophageal disorders, inability to remain upright), and counsel patients specifically about osteonecrosis of the jaw and atypical femoral fractures. 1

History to Obtain

Fracture Risk Assessment

• Previous fragility fractures (fractures from standing height or less, excluding skull, face, fingers, toes)
• Parental history of hip fracture
• Current glucocorticoid use (≥5 mg prednisone daily for ≥3 months)
• Smoking status (current smoker increases risk)
• Alcohol consumption (>2 units/day increases risk) 2
• Body weight (low BMI increases risk)

Secondary Causes of Osteoporosis

Screen for conditions that may cause or worsen bone loss:

• Thyroid disorders (hyperthyroidism, excessive thyroid replacement)
• Hyperparathyroidism
• Malabsorption syndromes (celiac disease, inflammatory bowel disease)
• Chronic kidney disease
• Rheumatologic conditions
• Hypogonadism
• Medications (chronic glucocorticoids, aromatase inhibitors, anticonvulsants)

Contraindications to Bisphosphonates

• Esophageal abnormalities (stricture, achalasia, Barrett's esophagus)
• Inability to stand or sit upright for 30-60 minutes after oral dose
• Severe renal impairment (serum creatinine ≥1.5 mg/dL or CrCl <30-35 mL/min depending on agent) 3
• Hypocalcemia (must be corrected before starting)
• Known hypersensitivity to bisphosphonates

Dental History

• Recent or planned invasive dental procedures (extractions, implants, oral surgery)
• Current dental infections or poor oral hygiene
• History of jaw problems or radiation to head/neck

This is critical because bisphosphonates increase risk of osteonecrosis of the jaw, particularly with invasive dental work 1

Laboratory Evaluation Required

Mandatory Labs Before Starting

• Serum creatinine - to calculate GFR and ensure adequate renal function
• Serum calcium - must correct hypocalcemia before initiating therapy
• 25-hydroxyvitamin D level - target ≥30 ng/mL before starting bisphosphonate 2
• Complete blood count - to exclude hematologic causes of bone loss
• Thyroid-stimulating hormone - to exclude hyperthyroidism

Additional Labs to Consider

• Serum phosphate and alkaline phosphatase - baseline bone turnover markers
• Parathyroid hormone - if hypercalcemia or suspected hyperparathyroidism
• 24-hour urine calcium - if history suggests hypercalciuria
• Tissue transglutaminase antibodies - if malabsorption suspected

Essential Patient Counseling

Administration Instructions (Critical for Efficacy and Safety)

For oral bisphosphonates:

• Take first thing in the morning on empty stomach with 8 oz plain water only
• Remain upright (sitting or standing) for 30-60 minutes after taking (30 min for risedronate/alendronate, 60 min for ibandronate)
• No food, drink, or other medications for 30-60 minutes after dose
• Do not lie down during this period to prevent esophageal irritation 4

Specific Adverse Events to Discuss

Osteonecrosis of the Jaw (ONJ):

• Rare but serious complication (risk increases with longer duration of therapy) 1
• Complete any needed invasive dental work BEFORE starting bisphosphonate
• Maintain excellent oral hygiene
• Have regular dental check-ups
• Report any jaw pain, swelling, numbness, or loose teeth immediately
• Inform dentist about bisphosphonate use before any dental procedures

Atypical Femoral Fractures:

• Rare complication associated with long-term use (>5 years) 1
• Report any new thigh or groin pain immediately, even without trauma
• These are stress fractures that can progress to complete fractures if not identified early

Common Side Effects:

• Gastrointestinal symptoms (nausea, heartburn, abdominal pain) - usually mild and transient
• Musculoskeletal pain - may occur but typically resolves
• Acute phase reaction with IV bisphosphonates (flu-like symptoms for 1-3 days after first dose)

Lifestyle Modifications (Non-Negotiable Adjuncts)

Calcium and Vitamin D:

• Target 1000-1200 mg elemental calcium daily (preferably from diet; supplement only if dietary intake insufficient) 2
• Vitamin D supplementation to maintain 25-OH vitamin D ≥30 ng/mL
• Take calcium and vitamin D supplements at different time from bisphosphonate (wait at least 30-60 minutes)

Other Lifestyle Factors:

• Protein intake: Ensure adequate protein (avoid low protein intake which worsens bone health) 2
• Weight-bearing exercise: Regular high-impact physical activity as tolerated
• Smoking cessation: Mandatory - smoking significantly increases fracture risk
• Limit alcohol: Maximum 2 units/day 2
• Reduce caffeine and sodium: Excessive intake increases calcium loss
• Fall prevention: Home safety assessment, vision check, medication review, balance exercises

Treatment Duration and Monitoring

Reassessment Timeline:

• After 3-5 years of oral bisphosphonates (3 years for zoledronic acid, 5 years for alendronate) 5
• Perform DXA scan and reassess fracture risk
• High-risk patients: Continue therapy
• Low-to-moderate risk patients: Consider "bisphosphonate holiday" (temporary discontinuation up to 5 years) 5
• During holiday: Reassess every 2-4 years with DXA; reinitiate if BMD declines significantly, new fracture occurs, or risk status changes

Important Caveat: Do NOT apply drug holiday concept to denosumab - stopping denosumab causes rapid bone loss and rebound fracture risk; requires transition to bisphosphonate if discontinuing 5

Medication Selection

First-line recommendation: Generic oral bisphosphonates (alendronate or risedronate) due to strong evidence, favorable cost, and availability 1

Dosing options to discuss with patient:

• Daily: Alendronate 10 mg or risedronate 5 mg
• Weekly: Alendronate 70 mg or risedronate 35 mg
• Monthly: Ibandronate 150 mg
• Annual IV: Zoledronic acid 5 mg (if oral not tolerated or contraindicated)

Patient preference matters for adherence - offer dosing frequency that fits patient's lifestyle 5

Documentation for Visit

Document the following in medical record:

• Fracture risk assessment and FRAX score (if applicable)
• Labs reviewed and abnormalities corrected
• Dental clearance obtained or planned
• Contraindications excluded
• Patient counseled on administration, adverse events (ONJ, atypical fractures), and lifestyle modifications
• Medication choice and rationale
• Plan for reassessment in 3-5 years

Common Pitfalls to Avoid

• Starting without correcting vitamin D deficiency - reduces bisphosphonate efficacy
• Inadequate administration counseling - leads to poor absorption and esophageal complications
• Ignoring renal function - bisphosphonates contraindicated in severe renal impairment 3
• Not addressing dental health - increases ONJ risk
• Continuing indefinitely without reassessment - increases risk of atypical fractures 1
• Applying bisphosphonate holiday principles to denosumab - causes dangerous rebound effect 5
• Forgetting calcium/vitamin D supplementation - bisphosphonates work best with adequate calcium and vitamin D